TCGA-DK-AA6T-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.79106439
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.450
- ALLOGRAFT_REJECTION+0.410
- MYC_TARGETS_V1+0.390
- MYC_TARGETS_V2+0.310
- PANCREAS_BETA_CELLS+0.220
- SPERMATOGENESIS+0.220
- DNA_REPAIR+0.180
- OXIDATIVE_PHOSPHORYLATION+0.130
- KRAS_SIGNALING_DN+0.090
Top 10 suppressed
- PROTEIN_SECRETION-0.580
- TGF_BETA_SIGNALING-0.500
- ANGIOGENESIS-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- NOTCH_SIGNALING-0.410
- ESTROGEN_RESPONSE_EARLY-0.400
- GLYCOLYSIS-0.370
- HYPOXIA-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- UV_RESPONSE_DN-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03080 | — | cohortSQ1 | 0.921 |
| 2 | SRR25617823 | — | D | 0.901 |
| 3 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.857 |
| 4 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.850 |
| 5 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.835 |
| 6 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.829 |
| 7 | C3L-00603 | — | cohortSQ1 | 0.826 |
| 8 | SRR5088865 | — | — | 0.821 |
| 9 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.820 |
| 10 | SRR934790 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |